Literature DB >> 25479942

Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice.

Shen-Cun Fang1, Hai-Tao Zhang, Hui-Di Hu, Cai-Ying Wang, Ying-Ming Zhang.   

Abstract

The present study was designed to investigate the synergetic effect of Endostar combined with an angiopoietin-2 specific inhibitor L1-10 on malignant pleural effusion (MPE) mouse model. A MPE mouse model was established by injecting Lewis lung carcinoma (LLC) cells into pleural cavity of C57BL/6 mice. The mice were randomly divided into four treatment groups: saline, Endostar, L1-10, and Endostar + L1-10. In the present study, we reported for the first time that Endostar combined with L1-10 had significant synergistic effects on the formation of MPE and tumor growth. Moreover, Endostar combined with L1-10 had additive effect on the attenuation of pleural inflammation, inhibition of tumor angiogenesis and pleural vascular hyperpermeability, which are central to the inhibition of MPE. Finally, these studies also found that Endostar combined with L1-10 could have complementary actions by reducing VEGF and IL-6 local release and downregulating VEGF expression in pleural tumors, which involved in the pathogenesis of MPE. Therefore, combined therapy with Endostar and L1-10 may be an encouraging strategy for the treatment of MPE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25479942     DOI: 10.1007/s12032-014-0410-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice.

Authors:  Xiao-Peng Dong; Tian-Hui Xiao; Hong Dong; Ning Jiang; Xiao-Gang Zhao
Journal:  Asian Pac J Cancer Prev       Date:  2013

2.  Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.

Authors:  Yu Zhang; Li-Ke Yu; Guo-Jun Lu; Ning Xia; Hai-Yan Xie; Wei Hu; Ke-Ke Hao; Chun-Hua Xu; Qian Qian
Journal:  Asian Pac J Cancer Prev       Date:  2014

3.  Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.

Authors:  Anil Bagri; Leanne Berry; Bert Gunter; Mallika Singh; Ian Kasman; Lisa A Damico; Hong Xiang; Maike Schmidt; Germaine Fuh; Beth Hollister; Oliver Rosen; Greg D Plowman
Journal:  Clin Cancer Res       Date:  2010-06-16       Impact factor: 12.531

Review 4.  Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.

Authors:  Masabumi Shibuya
Journal:  BMB Rep       Date:  2008-04-30       Impact factor: 4.778

5.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

Authors:  Nicolò Rigamonti; Ece Kadioglu; Ioanna Keklikoglou; Céline Wyser Rmili; Ching Ching Leow; Michele De Palma
Journal:  Cell Rep       Date:  2014-07-31       Impact factor: 9.423

Review 6.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

7.  The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.

Authors:  Charalampos Moschos; Ioannis Psallidas; Androniki Kollintza; Sophia Karabela; Andreas Papapetropoulos; Spyros Papiris; Richard W Light; Charis Roussos; Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Neoplasia       Date:  2009-03       Impact factor: 5.715

8.  Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model.

Authors:  Zi-Yu Jiang; Shu-Kui Qin; Xiao-Jin Yin; Ya-Li Chen; Lin Zhu
Journal:  Exp Ther Med       Date:  2012-05-18       Impact factor: 2.447

9.  Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.

Authors:  Hsuan-Heng Yeh; Wen-Tsan Chang; Kuang-Chu Lu; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice.

Authors:  Xingqun Ma; Yanwen Yao; Dongmei Yuan; Hongbing Liu; Shouju Wang; Changsheng Zhou; Yong Song
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more
  4 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 2.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

3.  Blockade of angiopoietin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in mouse cornea.

Authors:  Zhi-Xin Yan; Yi Luo; Ning-Fei Liu
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

4.  Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: A meta-analysis and systematic review.

Authors:  Cheng-Qian Wang; Fei-Yu Liu; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.